Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes

被引：439

作者：

Panee, Jun ^{[1
]}

机构：

[1] Univ Hawaii, John A Burns Sch Med, Dept Cell & Mol Biol, Honolulu, HI 96813 USA

来源：

CYTOKINE | 2012年 / 60卷 / 01期

关键词：

MCP-1; Inflammation; Obesity; Diabetes; Diabetic complications; NF-KAPPA-B; LOW-DENSITY-LIPOPROTEIN; HUMAN ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; HUMAN MESANGIAL CELLS; SMOOTH-MUSCLE-CELLS; MESSENGER-RNA EXPRESSION; PROLIFERATOR-ACTIVATED-RECEPTOR; BLOOD MONONUCLEAR LEUKOCYTES; HIGH GLUCOSE-CONCENTRATION;

D O I：

10.1016/j.cyto.2012.06.018

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

monocyte Chemoattractant Protein-1 (MCP-1) is the first discovered and most extensively studied CC chemokine, and the amount of studies on its role in the etiologies of obesity- and diabetes-related diseases have increased exponentially during the past two decades. This review attempted to provide a panoramic perspective of the history, regulatory mechanisms, functions, and therapeutic strategies of this chemokine. The highlights of this review include the roles of MCP-1 in the development of obesity, diabetes, cardiovascular diseases, insulitis, diabetic nephropathy, and diabetic retinopathy. Therapies that specifically or non-specifically inhibit MCP-1 overproduction have been summarized. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：1 / 12

页数：12

共 225 条

[1]

Abe D, 2010, BIOFACTORS

[2]

Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy [J].

Abu El-Asrar, Ahmed M. ;

Struyf, Sofie ;

Kangave, Dustan ;

Geboes, Karel ;

Van Damme, Jo .

EUROPEAN CYTOKINE NETWORK, 2006, 17 (03) :155-165

[3]

Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders [J].

AbuElAsrar, AM ;

VanDamme, J ;

Put, W ;

Veckeneer, M ;

Dralands, L ;

Billiau, A ;

Missotten, L .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 123 (05) :599-606

[4]

Common Variants of Inflammatory Cytokine Genes Are Associated with Risk of Nephropathy in Type 2 Diabetes among Asian Indians [J].

Ahluwalia, Tarunveer Singh ;

Khullar, Madhu ;

Ahuja, Monica ;

Kohli, Harbir Singh ;

Bhansali, Anil ;

Mohan, Viswanathan ;

Venkatesan, Radha ;

Rai, Taranjit Singh ;

Sud, Kamal ;

Singal, Pawan K. .

PLOS ONE, 2009, 4 (04)

[5]

ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1 [J].

Amann, B ;

Tinzmann, R ;

Angelkort, B .

DIABETES CARE, 2003, 26 (08) :2421-2425

[6]

An oral adsorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats [J].

Aoyama, I ;

Shimokata, K ;

Niwa, T .

NEPHRON, 2002, 92 (03) :635-651

[7]

Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction [J].

Arakelyan, A ;

Petrkova, J ;

Hermanova, Z ;

Boyajyan, A ;

Lukl, J ;

Petrek, M .

MEDIATORS OF INFLAMMATION, 2005, (03) :175-179

[8]

Activation of endoplasmic reticulum stress response during the development of ischemic heart disease [J].

Azfer, Asim ;

Niu, Jianli ;

Rogers, Linda M. ;

Adamski, Frances M. ;

Kolattukudy, Pappachan E. .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 291 (03) :H1411-H1420

[9]

Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy [J].

Banba, N ;

Nakamura, T ;

Matsumura, M ;

Kuroda, H ;

Hattori, Y ;

Kasai, K .

KIDNEY INTERNATIONAL, 2000, 58 (02) :684-690

[10]

Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways [J].

Bao, Yan ;

Jia, Ru-han ;

Yuan, Jun ;

Li, Jing .

PHARMACOLOGY, 2007, 80 (01) :57-64

← 1 2 3 4 5 6 7 8 9 10 →